Entrada Therapeutics, Inc.
TRDAHealthcare|Biotechnology|US
$4.89
+0.34 (+7.47%)
DCF Value
$9.63
Tangible Book / Share
$4.68
Cash / Share
$4.56
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07038824 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Duchenne Muscular Dystrophy (DMD) | P1P2 | Recruiting | 24 | RCT, Double-blind | ENTR-601-45, ENTR-601-45 - matching placebo |
| NCT07037862 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Duchenne Muscular Dystrophy (DMD) | P1P2 | Recruiting | 24 | RCT, Double-blind | ENTR-601-44, ENTR-601-44 - matching placebo |
| NCT07682129 Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | Duchenne Muscular Dystrophy (DMD) | P2 | Not Yet Recruiting | 80 | Open-label | ENTR-601-44, ENTR-601-45 |
| NCT04245917 Natural History Study of MNGIE | Mitochondrial Neurogastrointestinal Encephalomyopathy | SUSPENDED | 60 | — | — |